SOPH Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 8.09
- P/S (TTM)
- 4.93
- EV/EBITDA
- -0.30
Profitability & growth
- ROE (TTM)
- -110.0%
- Operating margin
- -85.4%
- Revenue growth YoY
- 22.4%
- Dividend yield
- —
- Beta
- 1.01
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Sophia Genetics SA
Company profileSophia Genetics SA (SOPH) is a trailblazer in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. Leveraging state-of-the-art machine learning algorithms, the company offers a robust platform that empowers hospitals and laboratories to decode complex genomic information, thereby enabling personalized treatment approaches, particularly in oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic alliances with leading healthcare institutions, Sophia Genetics is dedicated to revolutionizing…
Classification
- Sector
- Healthcare
- Industry
- Health Information Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- LA PIECE 12, ROLLE, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer